Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point.  We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.

Psylo

📣 Exciting new career opportunities at Psylo! 
 
At Psylo, we pioneer next-generation treatments for psychiatric and neurological conditions using our computationally-enhanced drug development platform.
 
We're growing and seeking passionate, skilled individuals for three key roles: 
 
1. Vice President of Drug Development: Clinical Readiness 
- Lead the charge in advancing our novel drug candidates from the lab to clinical trials.
- Location: Boulder, Colorado or Sydney, Australia.
 
2. Chemistry, Manufacturing, and Controls (CMC) Consultant 
- Collaborate globally to optimize lead compounds in our small molecule drug discovery programs.
- Location: Remote
 
3. Regulatory Affairs Consultant
- Guide and execute regulatory strategies for our drug development pipeline.
- Location: Remote
 
🚀 Why join Psylo?
- Be at the cutting-edge of scientific innovation.
- Thrive in a culture that values honesty, empathy, accountability, diversity, and self-reliance.
- Join a multidisciplinary team recognized as a Top 100 Innovator by The Australian Business Review, winner of the Hello Tomorrow 2023 APAC Competition, and a Top 50 Global Startup in SLINGSHOT 2023.
- Make a significant impact by contributing to the development of effective and accessible treatments.
 
Join us on our journey to revolutionize healthcare.
 
👉 Learn more and apply here: https://lnkd.in/gJGCn_SH 
 
#Psylo #BiotechJobs #DrugDevelopment #Neuroscience #Pharmacology #MentalHealth #CNS

🧏‍♀️ Did someone say innovation? Meet "the mental health startups of tomorrow" by attending this session at #DHF24, 7 & 8 May at Melbourne's MCEC.

Meet the panelists:
💙 Chair: Alon Greenspan, Partner, Mind Ventures
💙 Grace Brown, Founder, Andromeda
💙 Tia Cummins, PhD, CEO, Flintworks
💙 🧪 Joshua Ismin, Co-Founder & CEO, Psylo

🎟 Don't have tickets? Get 30% OFF tickets while they last: https://lnkd.in/g855KFDN

It was great to have a chance to speak with 💊 Sam Banister, co-founder and Chief Scientific Officer at Psylo for the Psychedelics Today podcast. Sam and I covered plenty of ground including what can be inferred by the volatility of biotech and the state of the psychedelic industry based on recent mergers and acquisitions, long-term challenges of drug development and the scalability of treatment options, how the initial success of Spravato has played a role in allaying fears around new compounds, head twitch response and its limitations in discerning between compounds which are non-hallucinogenic vs. non-psychoactive, and related topics. If you happen to give it a listen I hope you enjoy the conversation as much as I did.

The #ISRP meeting marks an unforgettable milestone in the history of psychedelic research.

The combination of high quality research, exceptional networking and the vibrant NOLA backdrop made it a truly unforgettable event.

It left us inspired and excited about the transformative potential of psychedelic research in mental health and beyond.

Big shout out to Charles Nichols, John Waslif and the team for putting on such a successful event! We can't wait for the next one.

The Psylo team is excited to be attending the renowned International Society for Research on Psychedelics (ISRP) meeting in vibrant New Orleans!

At Psylo, we're committed to exploring the untapped potential of the 5-HT2A receptor and its implications for mental health and well-being. 

This event presents an unparalleled opportunity to see the latest developments, exchange ideas, and stay at the forefront of this rapidly evolving field.

Stay tuned for updates and please reach out if you will be there. We love making new connections! 🧠

#Psylo #5ht2a #mentalhealth #biotech #ISRP 

Sydney's summer just got cooler with our chemistry team making ‘psychedelic’ snowflakes ❄

🧪 Joshua Ismin 💊 Sam Banister ⚗️ William Jorgensen Jin Tan Joanna Hare Lachlan Whish Nick Everett Mario de la Fuente, PharmD, PhD Dilara Bahceci Krista Licata Dr. Jianmin Duan Donald Gehlert, Ph.D. Kelly Burke

CrUX Dataset

Pound Sterling

CrUX Top 10m

Chemistry Research Assistant

Lachlan Whish

New South Wales Companies With Less Than $50M in Revenue (Top 10K)

Sydney Companies With Fewer Than 50 Employees (Top 10K)

Oceania Seed Stage Companies With Less Than $50M in Revenue

Possible Ventures Portfolio Companies

Psylo is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications.

Cooperative Research Centre Projects

Grant - Psylo

Tenmile

Seed Round - Psylo

Main Sequence Ventures

Possible Ventures

Sydney

New South Wales

Australia

Oceania

Superseeder: psychedelic biotech Psylo plants $12 million in latest 'Seed' round

Psylo Raises $8M in Seed Funding

Superseeder: psychedelic biotech Psylo plants $12 million in latest ‘Seed’ round

Psychedelic drug industry collaborations increased by 500% since 2019

Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC ...

United States

North America

Germany

Europe

ATAI is a biotech company focused on developing psychedelic compounds for various mental health conditions.

ATAI

COMPASS Pathways is a mental health care company that focuses on developing psilocybin therapy for treatment-resistant depression.

COMPASS Pathways

Beckley Psytech is a company dedicated to developing psychedelic medicines for the treatment of mental health disorders.

Beckley Psytech

CB Therapeutics is a biotechnology company specializing in the production of cannabinoids and other psychoactive compounds for therapeutic use.

CB Therapeutics

MindMed is a biotechnology company that develops psychedelic-inspired medicines to address mental health issues.

MindMed

Cybin is a biopharmaceutical company focused on developing psychedelic therapeutics for mental health disorders.

Cybin

Delix Therapeutics is a biotech company specializing in the development of novel treatments for mental health conditions.

Delix Therapeutics

Psilera is a biotechnology company dedicated to the development of psychedelic medicines for mental health disorders.

Psilera

Psylo is a technology company that specializes in the development of advanced software solutions for mental health professionals. The company leverages data analytics and machine learning to provide tools that enhance therapeutic outcomes and streamline clinical workflows.

news impact assignment basic	general
public peers	general	Jun 22, 2024 4:31 AM	21706d55
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jun 22, 2024 7:14 AM	560e41ae
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	1e31316f
crunchbase profile	general	Nov 25, 2024 11:08 AM	723e8623
li profile	general	Jun 22, 2024 4:31 AM	1251a299
translate crunchbase fundingrounds	general	Nov 25, 2024 2:13 PM	76219d97
peers	general
news basic	general	Jun 22, 2024 4:31 AM	3625e587
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIO:PSYLO

Psylo